Vilprafen

General characteristics. Structure:

Active ingrediyenty:1 the tablet, coated, contains 500 mg of a dzhozamitsin.
Other ingredients: microcrystallic cellulose, polysorbate 80, silicon the oxide besieged sodium carboxymethylcellulose, magnesium stearate, methyl cellulose, polyethyleneglycol 6000, talc, titanium dioxide, aluminum hydroxide, copolymer of methacrylic acid and its ethers.

Pharmacological properties:

Drug is used for treatment of bacterial infections; bacteriostatic activity of a dzhozamitsin, as well as other macroleads, is caused by inhibition of synthesis of protein of bacteria. During creation in the center of an inflammation of high concentration has bactericidal effect.
Dzhozamitsin is highly active concerning intracellular microorganisms (Chlamydia
trachomatis and Chlamydia pneumoniae, Mycoplasma pneumoniae, Mycoplasma hominis, Ureaplasma urealyticum. Legionella pneumophila); gram-positive bacteria (Staphylococcus aureus, Streptococcus pyogenes and Streptococcus pneumoniae (pneumococcus), Corynebacterium diphteriae), gram-negative bacteria (Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus influenzae, Bordetella pertussis), and also against some anaerobic bacteria (Peptococcus, Peptostreptococcus, Clostridium perfringens). Slightly influences enterobakteriya therefore changes a natural bacterial flora of digestive tract a little. It is effective at resistance to erythromycin. Resistance to a dzhozamitsin develops less than to other antibiotics from group of macroleads.

Pharmacokinetics. After intake джозамицин it is quickly and completely soaked up from digestive tract, meal does not influence bioavailability. The maximum concentration of a dzhozamitsin in serum is reached in 1-2 h after reception. About 15% of a dzhozamitsin contact proteins of plasma. Especially high concentration of substance are found in lungs, almonds, saliva, sweat and the lacrimal liquid. Concentration in a phlegm exceeds concentration in plasma by 8-9 times. Collects in a bone tissue. There passes the placental barrier, cosecretes in breast milk. Dzhozamitsin is metabolized in a liver to less active metabolites and excreted mainly with bile. Drug excretion with urine less than 20%.

Indications to use:

The acute and persistent infections caused by microorganisms, sensitive to drug, for example:
Upper respiratory tract infection and ENT organs
Quinsy, pharyngitis, peritonsillitis, laryngitis, average otitis, sinusitis; diphtheria (in addition to treatment by a diphtherial anatoxin), and also scarlet fever in case of hypersensitivity to penicillin.
Lower respiratory tract infections
Acute bronchitis, exacerbation of chronic bronchitis, pneumonia (including caused by atypical activators), whooping cough, a psittacosis.

- Dental infections. Ulitis and diseases of a parodont.
- Infections in ophthalmology. Blepharitis, dacryocystitis.
- Infections of integuments and soft tissues. A pyoderma, a furunculosis, a malignant anthrax, an ugly face (at hypersensitivity to penicillin), eels, a lymphangitis, lymphadenitis, a venereal lymphogranuloma.
- Infections of urinogenital system. Prostatitis, an urethritis, gonorrhea, syphilis (at hypersensitivity to penicillin), Chlamidia, mycoplasmal (including ureaplazmenny) and multi-infections.

Route of administration and doses:

The recommended daily dosage for adults and teenagers is aged more senior than 14 years makes from 1 to 2 g of a dzhozamitsin. The daily dose has to be divided into 2-3 receptions. The initial recommended dose makes 1 g of a dzhozamitsin.
In case of ordinary and spherical eels it is recommended to appoint джозамицин in a dose 500 mg twice a day within the first 2-4 weeks, further - 500 mg of a dzhozamitsin as the supporting treatment within 8 weeks once a day.
Coated tablets Vilprafen should be swallowed entirely, washing down with a small amount of water.
Usually duration of treatment is defined by the doctor. According to recommendations of World Health Organization about use of antibiotics duration of treatment of streptococcal infections has to make not less than 10 days.

Features of use:

At patients with a renal failure treatment should be carried out taking into account results of the corresponding laboratory tests.
It is necessary to consider a possibility of cross resistance to various antibiotics to macroleads (for example, the microorganisms steady against treatment by antibiotics, related on chemical structure, can also be rezistentna to a dzhozamitsin).

Side effects:

From digestive tract
Seldom - appetite loss, nausea, heartburn, vomiting, dysbacteriosis and diarrhea. In case of persistent heavy diarrhea it must be kept in mind a possibility of development against the background of antibiotics of life-threatening pseudomembranous colitis.
Hypersensitivity reactions
In extremely exceptional cases skin allergic reactions are possible (for example, a small tortoiseshell).
From a liver and biliary tract
  Tranzitorny increase in activity of hepatic was in some cases observed
enzymes in a blood plasma, in rare instances accompanied with disturbance of outflow of bile and jaundice.
From the hearing aid
It was in rare instances reported about a dozozavisimy passing hearing disorder.
Others
Very seldom - candidiasis.

Interaction with other medicines:

Vilprafen / other antibiotics
As bacteriostatic antibiotics can reduce bactericidal effect of other antibiotics, such as penicillin and cephalosporins, it is necessary to avoid joint purpose of a dzhozamitsin with these types of antibiotics. Dzhozamitsin it is not necessary to appoint together with lincomycin as perhaps mutual decrease in their efficiency.
Vilprafen / xanthines
Some representatives of antibiotics of macroleads slow down elimination of xanthines (theophylline)  that can lead to possible intoxication.  Kliniko-pilot studies indicate   what джозамицин exerts smaller impact on release of theophylline, than other antibiotics macroleads.
Vilprafen / antihistaminic drugs
After the joint purpose of a dzhozamitsin and antihistaminic drugs containing терфенадин or астемизол delay of removal of a terfenadin and astemizol can be noted that in turn can lead to development of life-threatening cardiac arrhythmias.
Ergot Vilprafen/alkaloids
There are individual messages on strengthening of vasoconstriction after joint purpose of alkaloids of an ergot and antibiotics of macroleads. One case of absence at the patient of tolerance to ergotamine at reception of a dzhozamitsin is noted. Therefore the accompanying use of a dzhozamitsii and ergotamine has to be followed by the corresponding control of patients.
Vilprafen / cyclosporine
Joint purpose of a dzhozamitsin and cyclosporine can cause increase in level of cyclosporine in a blood plasma and creation of nephrotoxic concentration of cyclosporine in blood. It is regularly necessary to control concentration of cyclosporine in plasma.
Viljprafen / digoxin
At joint purpose of a dzhozamitsin and digoxin increase in level of the last in a blood plasma is possible.
Vilprafen / hormonal contraceptives
In rare instances the contraceptive effect of hormonal contraceptives can be insufficient during treatment macroleads. In this case it is recommended to use non-hormonal contraceptives in addition.

Contraindications:

- hypersensitivity to antibiotics – macroleads
- heavy abnormal liver functions

Pregnancy and lactation. Use at pregnancy and during breastfeeding according to indications is authorized. The European department of WHO recommends джозамицин as choice drug at treatment of a chlamydial infection at pregnant women.

Overdose:

 There are no data on specific symptoms of poisoning so far.  In case of overdose  it is necessary to assume emergence of the symptoms described in the section "Side effects", especially from digestive tract.
If one reception is missed, it is necessary to accept a drug dose immediately. However, if time of reception of the following dose came, it is not necessary to accept the "forgotten" dose, and it is necessary to return to the usual mode of treatment. It is not necessary to accept the doubled dose. Having rummaged in treatment or the premature termination of administration of drug reduce probability of success of treatment.

Storage conditions:

Period of validity 4 years. Vilprafep it is not necessary to apply after the expiry date specified on packaging. List B. To store at a temperature not above 25 °C in the place protected from light. To store medicine in the places unavailable to children!

Issue conditions:

According to the recipe

Packaging:

1 coated tablet contains 500 mg of a dzhozamitsin.
Standard packaging: 10 coated tablets in the blister, 1 blister in a cardboard pack.